跳到主要内容
Learn Motion
探索课程产品能力价格

下载 Learn Motion

用手机扫描二维码,下载 App。

App Store

扫码从 App Store 下载 Learn Motion打开商店页面

Google Play

扫码从 Google Play 下载 Learn Motion打开商店页面
登录
Learn Motion

Why AI-Designed Drugs Haven't Changed Medicine Yet

1The Promise and the Puzzle2From Molecule to Medicine: The Journey a Drug Must Survive3Where AI Actually Helps in the Pipeline4The Prediction Gap: When a Good Molecule Meets a Real Body5The Long, Expensive Road of Clinical Trials6Money, Incentives, and the Business of Drug Development7Regulation, Evidence, and Trust8What Would Have to Change
What Would Have to Change

Reading the Early Signals

3 / 4
Take the three signals in turn and ask what each one would have to do to count as evidence. A trial readout counts because it is the point where someone outside the company can check the claim, and the interesting question is not whether one drug worked but whether the reasons for failure are changing. Regulatory guidance counts because agencies write rules for things that have become common enough to need them, so guidance tends to trail practice and its appearance tells you practice already moved. Adoption data counts because the last filter is the one inside the clinic, and a drug nobody prescribes has not changed anything. Now notice the trap: each of these is weak alone. One good trial can be luck, one guidance document can be routine paperwork. You are looking for a pattern that holds across several of them for several years, and that is a much higher bar than any single headline.
0:00 / 0:00

Where change would appear first

  • Trial readouts: published results of completed human studies, where a benefit claim becomes checkable and where a change in the pattern of failures would be informative
  • Regulatory guidance: published expectations for how a novel design method must be documented, which typically appears after a method has become common in practice
  • Adoption data: prescribing patterns, formulary decisions, and clinician commentary, which reveal whether approved drugs are actually reaching patients

Why single signals mislead

One successful trial can be a favorable draw from a noisy process. One guidance document can be routine. The informative thing is a sustained pattern across several signal types over several years, not any individual announcement.

上一页3 / 4下一页

Learn Motion

生成课程,认真学会。

运营方:Wuhan Daoyin Technology Co., Ltd.

联系我们: [email protected]
隐私政策用户服务协议

© 2026 Learn Motion